Core Viewpoint - BGM Group is set to release its unaudited financial results for the first half of 2025 on July 24, 2025, before U.S. financial markets open [1] Company Overview - BGM Group Ltd. focuses on technology sectors including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [2] AI Application Implementation - The company utilizes advanced analytics and AI Agent technology through its platforms Du Xiao Bao and Bao Wang to deliver AI solutions and intelligent robot services to insurance companies, brokers, and consumers [3] - Services encompass sales and marketing, underwriting assessment, claims processing, and customer service, with capabilities in consumer data analysis and customized service provision [3] Biopharmaceuticals Division - BGM's biopharmaceutical division produces oxytetracycline API, crude heparin sodium, and licorice preparations, serving global markets in animal husbandry, pharmaceuticals, and drug retail [4] - The integration of AI-assisted decision-making enhances production efficiency, supply chain optimization, and market trend prediction, providing a scientific basis for management decisions and high-quality products for consumers [4]

Group 1 - BGM Group Ltd. has completed the acquisition of YX Management Company Ltd., enhancing its capabilities in intelligent mobility technology, with a valuation of US$95.0 million [1][2] - Following the acquisition, YX's shareholders own approximately 32.6% of BGM's equity interests and about 2.2% of the total voting power [1] - The acquisition is a significant step in BGM's AI-driven transformation, aimed at integrating AI into its core businesses, including intelligent insurance and digital services [2][3] Group 2 - The CEO of BGM stated that the integration of YX's expertise will accelerate the application of AI across key sectors, advancing towards an AI Agent-driven model [3] - BGM focuses on technology fields such as AI application, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [4] - The group utilizes advanced analytics and AI Agent technology to provide comprehensive AI solutions for insurance companies, covering various key scenarios [5] Group 3 - In the biopharmaceutical sector, BGM's division produces oxytetracycline API, crude heparin sodium, and licorice preparations, integrating AI-assisted decision-making for supply chain optimization [6]